China has such a dominant position in active pharmaceutical ingredient (API) production that there is a risk it could "weaponise" access, according to a new congressional report. The document, from ...
Subscribe to our weekly newsletter for the latest in industry news, expert insights, dedicated information security content and online events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results